Introduction
Immune-based therapy for HIV treatment and prevention:
A review of clinical endpoints for trials of immunologic agents
Early in the HIV epidemic, clinical trials of AIDS drugs followed the model of cancer-drug trials, which were commonly based on the endpoint of 5-year survival. This endpoint, however, in the era before highly active antiretroviral therapy, was impracticable given the rapid time course of disease progression to AIDS and eventual death. On December 11, 1992, the U.S. Food and Drug Administration issued a final rule whereby approval for certain new drugs and biological products for serious or life-threatening illnesses could receive accelerated approval with provisions for any necessary continued study of the drugs' clinical benefits after approval or with restrictions on use, if necessary. 1 The FDA will consider accelerated approval for a drug or biological product in two situations, the first of which is relevant here:
When approval can be reliably based on evidence from adequate and wellcontrolled studies of the drug's effect on a surrogate endpoint that reasonably suggests clinical benefit or on evidence of the drug's effect on a clinical endpoint other than survival or irreversible morbidity, pending completion of studies to establish and define the degree of clinical benefits to patients [emphasis added]. 1 One comment received on the rule noted that:
Approval based on surrogate endpoints is not new, although the issue has not previously been considered in regulations. The agency has, in a number of instances, approved drugs based on surrogate endpoints. For example...drugs for hypercholesterolemia have been approved based on effects on serum cholesterol rather than on coronary heart disease (angina, heart attacks)....But, there was very good evidence from clinical trials...that improving the surrogate would lead to or is associated with the desired effects on morbidity and mortality. Even so, there is still today considerable debate about who will benefit from lowering cholesterol. Controlled trials assessing effects on clinical endpoints of morbidity and mortality from use of cholesterol-lowering drugs have been, and are being, conducted. 1 The general standard for approval of AIDS drugs evolved to be improved survival or delayed progression to an AIDS-defining opportunistic condition. In a clinical endpoint trial, the new drug must be shown to be at least as good as some standard treatment in reducing death or major disease progression in some group of patients. 2 Clinical endpoint trials present a spectrum of problems, though, including the following:
• need for a thousand or more volunteers • requirement for at least one year of actual time on treatment • questionable ethics of asking volunteers to remain in suboptimal treatment arms. 2 In light of these problems, the trend in trials of HIV therapies has been toward surrogate markers of clinical efficacy. In current studies, primary endpoints are often virologic and clinical, with secondary endpoints being immunologic or assay-dependent. Study sample sizes are more often based on the need to detect differences in the magnitude or duration of the virologic effect, rather than clinically significant differences. It is important to note, however, that virologic failure and clinical failure are not equivalent.
Virologic failure may precede immunologic and clinical failure by months or years. No one yet knows how long it will take for a person experiencing a viral load rebound to progress to a clinical endpoint-an AIDSdefining illness or death. 3 In lieu of a clinical endpoint, clinical trials of HIV therapies have moved away from the cancer-trial model and now rely more upon CD4+ cell count and viral load as surrogate markers. This shift is reflected in trends in antiretroviral study designs:
• Clinical endpoints, such as progression to AIDS and death, have become less practical, whereas laboratory measurements and treatment history have become important factors in trial design and analysis.
• Studies that once used CD4+ cell count thresholds for entry or exclusion criteria are relying increasingly on viral load thresholds.
• Many studies have restrictions related to prior therapy (e.g., protease-inhibitor naïve)
• As the use of laboratory measurements has increased and the incidence of clinical endpoints has declined, studies are becoming smaller and their duration shorter.
• Studies appear to be attempting to answer several questions at once. For example, they are simultaneously attempting to validate the use of new doses, new treatment combinations, and new diagnostic tests (such as genotypic or phenotypic resistance assays). 3 Because the human immune response to HIV infection is effective at keeping the virus suppressed for a number of years, a focus of current HIV research has been immune-based therapies that attempt to bolster the patient's immune system, 4 sometimes in tandem with antiretroviral therapy to suppress viral load. With the introduction of immune-based therapies, new, diverse surrogate markers are needed to monitor immune status and reflect viral burden. To widen the search for endpoints and surrogates that may be applicable to trials of immune-based therapies in HIV infection, the Forum for Collaborative HIV Research reviewed phase II and phase III trials of a dozen or so immune-based therapies. The results of that review have been summarized on fact sheets, which highlight relevant immune-based therapies, scrutinizing each study's design, as well as primary and secondary clinical endpoints. The first 8 immunebased therapies have been approved by the FDA for treatment of conditions other than HIV infection. The remaining fact sheets summarize immune-based therapies that have been evaluated or are currently being evaluated in phase II or phase III trials with HIV-infected individuals. These trials, too, are examined with an eye to study design and endpoints.
The endpoints, outcomes, surrogates, and assessments used in the supporting clinical trials involve a spectrum of clinical and immunological surrogates because they are addressing a wide variety of conditions. Some of them-tumor size, transplant rejection-clearly do not apply to the clinical setting of HIV infection, but others--quality of life assessment, gene rearrangement, C-reactive protein concentration, delayed hypersensitivity to recall antigens-may be exploited to gauge potential effects on immune reconstitution, viral load reduction, or development of protective immunity. By looking across the phase II and phase III clinical trials of the immune-based therapies scrutinized for this review, one can see that the study endpoints tend to fall into several broad categories. The table below shows the results of this "analysis."
Endpoints for efficacy trials of immune-based therapies.
Endpoint category Endpoints

Immunologic parameters
Immunoglobulin When a repertoire of appropriate surrogate markers is available to correlate with increased resistance to infections, reduced disease progression, and clinical survival, 5 additional protocols for clinical trials of immune-based therapies can be developed and implemented to rapidly and accurately assess how effectively these therapies prolong survival, protect against infection, and improve quality of life.
FDA-approved immune-based therapies
Interferon-beta-1a
On May 17, 1996, the U.S. Food and Drug Administration approved use of interferon-beta-1a (Avonex) for treating relapsing forms of multiple sclerosis in order to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. 6 The amino acid sequence of Avonex is identical to that of natural human interferon beta. It is produced by mammalian cells (Chinese hamster ovary cells) into which the human interferon beta gene has been introduced. 7 The basis for approval was a multicenter, phase III study conducted by Jacobs et al. 8 The study involved 301 patients who were randomized into a double-blinded, placebo-controlled trial. Sample size calculation was based on a Kaplan-Meier analysis and an intent-to -treat design. The expected placebo progression rate was based on the median time to progression (104 weeks) in the placebo arm of another clinical trial. The study was designed to have a statistical p ower of 80% to detect a group difference of this magnitude with an á level of .05. Interferon-beta-1a was administered intramuscularly at a dosage of 6.0 million units (30 ìg) weekly for up to 104 weeks.
The primary clinical endpoint was time to sustained disability progression of at least 1.0 point on the Kurtzke expanded disability status scale (EDSS) 9 . The EDSS is a quantitative clinical rating scale of neurological impairment with scores ranging from 0 to 10; increasing numbers reflect increasing disability. Only objectively verifiable defects due to multiple sclerosis as elicited upon neurologic examination are included. This endpoint was used to ensure that progression reflected a permanent increase in disability rather than a transient effect due to an exacerbation. 8 The Interferon-beta-1a was found to produce a significant delay in time to sustained EDSS progression (P = .02).
Two major secondary endpoints were also evaluated: exacerbation frequency and results of magnetic resonance imaging (MRI) scans to evaluate lesion number and volume. Additional secondary endpoints included two upper limb (tested in both arms) and three lower limb function tests. Patients treated with interferon-beta-1a had significantly fewer exacerbations (P = .03), which were defined by the appearance of new neurological symptoms or worsening of preexisting neurological symptoms lasting at least 48 hours in a patient who had been neurologically stable or improving of the previous 30 days accompanied by objective change on neurological examination (worsening of 0.5 point on the EDSS or a worsening by a point or more within one of the FS scores). 8 Furthermore, the patients treated with interferon-beta-1a had a significantly lower number and volume of gadolinium-enhanced brain lesions on magnetic resonance images (P values ranging between .02 and .05). T2 lesion volume measurements were based on a modification of a thresholding approach using the long-repetition time/short-echo time images. 8 Of the limb function tests, only one demonstrated a statistically significant difference between treatment groups (favoring interferon-beta-1a).
An additional multicenter, phase II study is underway to determine the tolerability and efficacy of 3 doses of interferon-beta-1a versus placebo in the treatment of idiopathic pulmonary fibrosis. In the laboratory, interferons have been shown to produce changes favoring reduction in collagen deposition and fibrosis. Treatment is aimed at minimizing the disease progression from inflammation to fibrosis. 10 An ongoing phase II trial is designed to determine the effectiveness of interferon-beta-1a to shrink recurring gliomas. 11 
Interferon alfa-n1, Lymphoblastoid
Interferon alfa-n1 (Wellferon) is a mixture of alpha-interferons isolated from a human lymphoblastoid cell line following induction with murine parainfluenza virus type 1 (Sendai strain) and purified by immuno-affinity chromatography. The lymphoblastoid cell and virus banks have been qualified and the production process validated to inactivate or remove known adventitious viruses and microorganisms. 13 On March 25, 1999, the U.S. Food and Drug Administration approved the use of interferon alfa-n1 for the treatment of chronic hepatitis C in patients 18 years of age or older without decompensated liver disease. 14 Glaxo-Wellcome has since ceased production of Wellferon. Heretofore, Wellferon had been available abroad and licensed in various countries for such indications as chronic hepatitis B, chronic hepatitis C, condylomata acuminata, juvenile laryngeal papillomatosis, chronic myeloid leukemia, hairy cell leukemia, Kaposi's sarcoma, and renal cell carcinoma. 15 The safety and efficacy of interferon alfa-n1 in the treatment of adult patients with chronic hepatitis C were established in 2 large trials that enrolled a total of 1,511 patients. The first 16 of the 2 trials, a multicenter, phase III, randomized trial (N = 440) compared 4 different regimens of interferon alfa-n1 administered subcutaneously: 3MU thrice weekly for 6 months, 5 MU thrice weekly for 6 months, 3 MU thrice weekly for 12 months, and 5 MU thrice weekly for 12 months. The primary clinical endpoint was the normalization of serum alanine transaminase (ALT) at the end of treatment and at 12 months post-treatment. Normalization of ALT was defined as the presence of 2 consecutive ALT values less than or equal to the upper limit of normal, at least 7 days apart. 16 A higher number of sustained responses was observed in patients treated with 3 MU of interferon alfa-n1 for 12 months than those treated for 6 months. Patients receiving 5 MU did not have significantly higher sustained response rates than those receiving 3 MU of interferon alfa-n1. 13, 16 The second major multicenter, phase III, open-label, randomized trial 17 (N = 1,071) compared treatment with interferon alfa-n1 to treatment with recombinant interferon alfa-2b, both given at 3 MU subcutaneously thrice weekly 13 for 6 months). The primary clinical endpoint was the normalization of serum ALT level with the principal treatment comparison occurring at the end of treatment (week 24). An end-of-treatment response in ALT levels was defined as the presence of 2 consecutive ALT values less than or equal to the upper limit of normal, at least 7 days apart and with a normal value at week 24. A second comparison on the primary treatment endpoint was sustained response, defined as an end-of-treatment response without relapse between weeks 24 and 48 and weeks 24 and 72. 5 Interferon alfa-n1 and interferon alfa-2b had similar end-of-treatment response rates, but the sustained response rate was higher with interferon alfa-n1. 17 Secondary endpoints for both studies were assessment of clearance of serum hepatitis C virus (HCV) RNA and histological improvement as evidenced by the liver biopsies post-treatment. The presence and level of HCV RNA in serum was determined by an unvalidated quantitative reverse transcription polymerase chain reaction (RT-PCR) targeted to the 5' noncoding region of the HCV genome. The assay cutoffs were <100 HCV RNA copies per milliliter. Subjects who received 3 MU thrice weekly of interferon alfa-n1 for 6 months had a virologic response rate of 17.3% 1 year after therapy. The study results suggested a correlation between sustained normalization of serum ALT levels and clearance of detectable serum HCV RNA at the end of post-treatment observation. 17 Baseline liver biopsies were performed within 12 months before initiation of treatment. Follow-up liver biopsies were obtained at weeks 24 and 72. 16, 17 Blinded liver biopsies were assessed and scored separately for total (portal, periportal plus lobular) necroinflammatory activity (grade) and fibrosis (stage) using the components of Knodell's histological activity index (HAI) score. 18 The HAI generates a numerical score for asymptomatic chronic active hepatitis liver biopsy specimens. Biopsy specimens are graded in 4 categories:
• periportal +/-bridging hepatocellular necrosis, graded from 0 ( none) to 10 (multilobular necrosis)
• intralobular degeneration and focal hepatocellular necrosis, graded from 0 (none) to 4 (marked, involving more than 2/3 of lobules or nodules) • portal inflammation, graded from 0 (no portal inflammation) to 4 (marked, with dense packing of inflammatory cells in more than 2/3 of portal tracts) • fibrosis, graded from 0 ( no fibrosis) to 4 ( cirrhosis). 18 Note that periportal necrosis +/-bridging necrosis is weighted more heavily than other parameters because it appears to be more influential in determining the activity and severity of severe chronic active hepatitis. A numerical score for each category is assigned to each biopsy, and the combined score of the four categories forms the HAI score for that biopsy specimen. 6 In Farrell's study, liver histology in patients who had an end-of-treatment response was improved in 57% of patients, as indicated by a 2-point or greater reduction in the total necroinflammatory activity score of the HAI compared with 38% in nonresponders. There were no differences in liver histology between the groups treated with inte rferon alfa-n1 or with interferon alfa-2b. 17 A review of the literature revealed an additional phase III study of interferon alfa-n1 in combination chemotherapy for treatment of advanced malignant melanoma, 19 although no details were available about study design or clinical endpoints.
Interferon alfacon-1
On October 16, 1997, the U.S. Food and Drug Administration (FDA) approved the use of interferon alfacon-1 (Infergen), a recombinant, non-naturally occurring, type-I interferon, for treatment of chronic hepatitis C infection in patients 18 years or older with compensated liver disease who have anti-HCV serum antibodies and/or the presence of HCV RNA. 20 Interferon alfacon-1, also called consensus interferon, was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. 21 FDA approval was granted on the basis of two published clinical trials. 22,23 Tong et al. 22 compared interferon alfacon-1 treatment to a standard regimen of recombinant interferon alfa-2b. This study was a multicenter, doubleblind, parallel-group, phase III clinical trial involving 704 patients randomized to receive interferon alfacon-1 at doses of 3 or 9 ìg, or interferon alfa-2b at 15 ìg (3 million units) subcutaneously thrice weekly for 24 weeks, followed by a 24-week posttreatment observation period. 22 Tong et al. assessed the efficacy of interferon alfacon-1 on an intent-to -treat basis using a primary clinical endpoint of normalization of serum alanine transaminase (ALT) concentration. Baseline ALT was the average of four ALT measurements determined during the screening and pretreatment observation periods. At baseline, the mean serum ALT concentrations were 140!61, 147!63, and 151!70 U/L in the 3-ìg interferon alfacon-1 group, the 9-ìg interferon alfacon-1 group, and the 15-ìg interferon alfa-2b group, respectively. By the end of the 24-week treatment period, the mean serum ALT concentrations decreased to (respectively) 118 108!76, respectively. Qualitatively, 16.8%, 42.2%, and 36.7% of the patients in the 3-ìg interferon alfacon-1 group, the 9-ìg interferon alfacon-1 group, and the 15-ìg interferon alfa-2b group, respectively, experienced normalization of their serum ALT concentrations at the end of the 24-week treatment period. By the end of the 24-week posttreatment observation period, however, 6.5%, 20.3%, and 19.6% of the 3-ìg interferon alfacon-1 group, the 9-ìg interferon alfacon-1 group, and the 15-ìg interferon alfa-2b group, respectively, had serum ALT concentrations that were within the normal range. 22 The study of Tong et al. was designed around 4 secondary endpoints: (1) decrease in serum hepatitis C virus RNA concentration below the limit of detection by reverse-transcription polymerase chain reaction (100 copies/mL); (2) liver histology; (3) differences in response rates between the two interferons; and (4) ALT and HCV RNA responses by HCV genotype. 22 This clinical trial was the first one to document the impact of interferon therapy on HCV RNA concentrations in a large, prospective, randomized, double-blind study. The baseline serum HCV RNA concentration for each patient was calculated as the mean of the HCV RNA concentrations determined 12 weeks before the study and at time 0. Serum HCV RNA concentrations were determined at weeks 12, 20, 24, 36, 44, and 48 using a quantitative, multicycle RT-PCR method (National Genetics Institute, Culver City, CA). Response to therapy was determined both quantitatively (reduction in serum HCV RNA) and qualitatively (proportion of patients with serum HCV RNA below the limits of detection). 22 Liver biopsy specimens were obtained within the 12-month period before enrollment and at the end of the posttreatment observation period (week 48). The biopsies were evaluated using Knodell's histological activity index (HAI), 24 a numerical score for asymptomatic chronic active hepatitis liver biopsy specimens. Biopsy specimens are graded in four categories:
• intralobular degeneration and focal hepatocellular necrosis, graded from 0 (none) to 4 (marked, involving more than two-thirds of lobules or nodules) • portal inflammation, graded from 0 (no portal inflammation) to 4 (marked, with dense packing of inflammatory cells in more than two-thirds of portal tracts) • fibrosis, graded from 0 ( no fibrosis) to 4 ( cirrhosis). 24 Note that periportal necrosis +/-bridging hepatocellular necrosis is weighted more heavily than other parameters because it appears to be more influential in determining the activity and severity of severe chronic active hepatitis. A numerical score for each category is assigned to each biopsy, and the combined score of the four categories of the four categories forms the HAI score for that biopsy specimen. 5 The mean changes in the HAI scores were -1.73, -2.01, and -2.03 units for the 3-ìg interferon alfacon-1 group, the 9-ìg interferon alfacon-1 group, and the 15-ìg interferon alfa-2b group, respectively. The changes were attributed primarily to reductions in inflammation. There was at least a 2-unit improvement in the HAI score at the e nd of the posttreatment period in 52% to 55% of the patients in the three cohorts, although there were no statistically significant differences among the three treatment groups. Patients who were responders by the ALT or HCV RNA criteria had statistically significantly greater improvement in HAI scores compared to patients who were not ALT or HCV RNA responders (P < .001 for both comparisons). 22 Patients infected with HCV genotypes 2 (39%) and 3 (48%) exhibited significantly higher response rates compared to those infected with genotype 1 (14%) at the end of the treatment period (P < .001), independent of treatment regimen. The differences persisted through the end of the observation period as well. 22 A second study by Keeffe et al. 23 was instituted, drawing on 337 patients from the initial phase III study who had relapsed or had not responded to 24 weeks of therapy with interferon alfacon-1 or interferon alfa-2b. In this double-blind, open-label, retreatment study, patients were randomized to receive 15 ìg of interferon alfacon-1 administered thrice weekly for either 24 or 48 weeks. Keeffe et al. relied upon the same primary and secondary clinical endpoints as Tong et al. 22 Retreatment of nonresponders with a higher dose of interferon alfacon-1 (15 ìg) produced end-of-retreatment response rates of 19% and 17% in the 24-and 48-week retreatment cohorts, respectively, and serum HCV RNA sustained response rates of 5% and 13%, respectively. Relapsers were more likely to respond to retreatment than nonresponders. The serum HCV RNA end-of-retreatment response rates in relapsers were 72% and 76% in the 24-and 48-week retreatment cohorts, respectively. By comparison, the serum HCV RNA sustained response rates, as determined at the end of the posttreatment observation period, in relapsers were 28% and 58% in the 24-and 48-week retreatment cohorts, respectively. 23
Rituximab
On November 26, 1997, the U.S. Food and Drug Administration approved use of rituximab (Rituxan) for treating patients with relapsed or refractory low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma. 25 Rituximab, the first monoclonal antibody approved to treat cancer, 26 is a chimeric murine-human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. 27 The clinical efficacy of rituximab was demonstrated in 4 clinical trials, which served as the basis for FDA approval. The pivotal clinical trial, a phase III multicenter, open-label, single-arm study, 28 showed that 48% o f the intent-to -treat group responded to treatment, with 6% achieving a complete response and 42% achieving a partial response. 26 The study involved 166 patients who received antibody doses of 375 mg/m 2 , administered intravenously once weekly for a total o f four infusions (days 1, 8, 15, 22). Time to progression was analyzed by the Kaplan-Meier method. 28 For this pivotal trial, clinical endpoints were defined in terms of complete or partial response and time to progression. Complete response (CR) required the resolution of all symptoms and signs of lymphoma, including bone marrow clearing, for at least 28 days as evidenced by computed tomography (CT) scans. Partial response (PR) required a decrease of at least 50% in the sum of the products of perpendicular measurements of lesions, without 25 
who did not achieve a CR or PR, the majority (56 of 75) had a net decrease of measurable disease (mean decrease, 32%). Time to progression was measured from the first infusion until progression. The projected median time to progression for responders was 13.0 months for the intent-to -treat group and 12.5 months for the assessable group. Within a median follow-up duration of 11.8 months, 53 of the 76 responders had not yet relapsed. 28 Several immunologic parameters were followed during the study, although they were not specifically identified as secondary endpoints. The median B-cell count declined with treatment to undetectable levels after the first dose for the majority. A minority of patients (16/166) did not deplete circulating B cells. The mean serum IgM level had decreased to 541.5 mg/dL (normal range, 45 to 145 mg/dL) at 6 months posttreatment. Twenty-three of the 166 patients had reductions in immunoglobulin levels by > 50% to subnormal levels. A > 20% decrease from baseline in serum complement (C3) was noted in 18/166 patients. Cells with bcl-2 gene rearrangement were detected pretreatment by polymerase chain reaction in the peripheral blood of 66 patients and in the bone marrow of 52 patients. For those who had serial monitoring, reversion to negative status (no detectable rearranged cells by PCR) occurred in the peripheral blood in 19% following the first infusion, 50% before the fourth infusion, and 62% by 3 months. In the bone marrow, reversion to negative was seen in 56% at 3 months. Median serum levels of rituximab were higher for responders than nonresponders. Attainable serum rituximab concentrations correlated negatively with the number of circulating B cells, with the size of the largest pretreatment measurable tumor, and with the baseline sum of the products of the diameters of the 6 largest lesions. 28 A second, phase II, open-label, single-arm, multicenter trial evaluated efficacy of 4 intravenous infusions of rituximab at a dose of 375 mg/m 2 in 37 patients with relapsed, low-grade non-Hodgkin's lymphoma. 29 Patients received a single infusion weekly and completed the 4 antibody infusions in 22 days. Clinical endpoints were defined in terms of CR, PR, or stable disease. CR was defined as the disappearance of all disease. PR required a decrease of at least 50% in the sum of the products of perpendicular measurements of lesions, without any evidence of progressive disease for at least 28 days. Stable disease was defined by no significant change in tumor measurements without progression over the period of observation. Clinical responses were observed in 17 of the 37 patients (46%), with 9% showing CR and 41% showing PR. Thirty-two percent had stable disease, and 18% were judged to have progressive disease. The median time to onset of clinical response for the 17 responders was 50 days. The median duration of response was 8.6 months. 29 Again, several other immunologic parameters were monitored. B-cells were rapidly and effectively depleted from peripheral blood circulation. Circulating B-cells remained nearly undetectable until approximately 6 months posttreatment, followed by slow gradual recovery. A significant correlation was observed between clinical response and median levels of circulating rituximab before the second infusion, with responders having a median of serum level of 83 ìg/mL versus nonresponders with a median of 22 ìg/mL. Mean serum immunoglobulin levels remained stable. No clinically significant change in serum complement levels was observed. 29 A third, phase II, open-label, single-arm, multicenter trial demonstrated the safety and efficacy of rituximab in 31 patients with bulky (> 10-cm lesion) relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. 30 Clinical endpoints included overall response rate (CR and PR), time to progression, and response duration. Response categories consisted of CR, PR, stable disease, and progressive disease. CR required that all lymph nodes visible on CT scans of neck, chest, abdomen, and pelvis be less than 1 cm x 1 cm; any node that was palpable on physical examination be no longer palpable or negative on biopsy or fine-needle aspirate; bone marrow must have been histologically negative for lymphoma; and the liver and spleen (if abnormal at baseline) must have returned to normal size. PR was defined as > 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters of all the measured lesions. The overall response rate in 28 assessable patients was 43% with a median time to progression of 8.1 months. As in the other trials, median serum rituximab concentrations were higher in responders than in nonresponders, with higher concentrations being associated with lower tumor bulk. In contrast to the pivotal trial, however, there was no correlation between serum rituximab concentration and the number of circulating B cells. 30 Finally 
Rituximab is being tested in Europe in patients with other B-cell malignancies, including mantle cell lymphoma, Waldenström's macroglobulinemia, and lymphoplasmacytoid lymphoma. 32 
Infliximab
Infliximab (Remicade), a chimeric monoclonal antibody that binds specifically to human tumor necrosis factor alpha (TNF-alpha), 34 has been approved by the U.S. Food and Drug Administration (FDA) for two indications:
• On August 24, 1998, infliximab was approved for the treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's d isease for the reduction in the number of draining enterocutaneous fistula(s). 35 • On November 10, 1999, FDA approved the use of infliximab for reducing signs and symptoms of rheumatoid arthritis in patients who have had an inadequate response to methotrexate . 36 The clinical efficacy of infliximab for treating active Crohn's disease was demonstrated in a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of 108 patients with moderate to severe active Crohn's disease. 37 Patients were randomly assigned to receive a single 2-hour intravenous infusion of either placebo or infliximab in a dose of 5, 10, or 20 mg per kilogram of body weight. The primary clinical endpoint was defined as a reduction of 70 points or more in the score on the Crohn's Disease Activity Index 38 (CDAI) at the 4-week evaluation 34 Centocor, Inc. Remicade prescribing information. 35 that was not accompanied by a change in any concomitant medications. 37 The CDAI incorporates 8 disease-related variables: the number of liquid or very soft stools, the severity of abdominal pain or cramping, general well-being, the presence of extraintestinal manifestations, abdominal mass, use of antidiarrheal drugs, hematocrit, and body weight. These items yield a composite score ranging from 0 to approximately 600. Higher scores indicate greater disease activity. Scores below 150 indicate remission, whereas scores above 450 indicate severe illness. 38 At week 4, 16% of the placebo patients achieved a clinical response compared to 82% of patients receiving 5 mg/kg infliximab. Four percent of placebo patients and 48% of patients receiving 5 mg/kg infliximab achieved a CDAI <150 at week 4. 34 Secondary clinical endpoints were increased score for the Inflammatory Bowel Disease questionnaire 39 and decreased C-reactive protein concentration. 37 The Inflammatory Bowel Disease questionnaire consists of 32 items that evaluate quality of life with respect to bowel function (e.g., loose stools and abdominal pain), systemic symptoms (e.g.,fatigue, altered sleep pattern), social function (work attendance and the need to cancel social events), and emotional status (angry, depressed, or irritable). The score ranges from 32 to 224, with higher scores indicating a better quality of life. Patients in remission usually score between 170 and 190. 39 During the 12-week p eriod following infusion, patients treated with infliximab compared to placebo demonstrated improvement in outcomes as measured by the questionnaire. 34 C-reactive protein concentration decreased by an average of 14.3 mg/L for all infliximabtreatment groups, whereas C-reactive protein concentration increased by 2.0 mg/L for the placebo group. 37 Safety and efficacy of infliximab for treating fistulizing Crohn's disease were assessed in a randomized, double-blind, placebo-controlled study of 94 patients who had draining abdominal or perianal fistulas of at least 3 months' duration. 40 The primary clinical endpoint was defined as a reduction of 50% or more from baseline in the number of draining fistulas observed at two or more consecutive study visits. With respect to the primary efficacy endpoint, response rates were significantly greater among the patients receiving infliximab (68%) than in the placebo group (26%). Secondary clinical endpoints evaluated the number of patients with a complete response (defined as the absence of any draining fistulas at two consecutive visits), the length of time to the beginning of a response, the duration of the response, and changes in scores on the CDAI and the Perianal Disease Activity Index. Complete responses were achieved in 55% of patients treated with 5 mg infliximab per kilogram, in 38% of those treated with 10 mg/kg, and in 13% of patients receiving placebo. The median time to the onset of a response was shorter among patients treated with infliximab (2 weeks) than among those given placebo (6 weeks). The median duration of response was approximately 3 months in patients who reached the primary endpoint.
Infliximab was shown to be safe and efficacious for treatment of rheumatoid arthritis 34 in a multicenter, randomized, double-blind, placebo-controlled, phase III trial involving 428 patients with active rheumatoid arthritis despite treatment with methotrexate. 41 The patients were randomized to receive placebo, 3 mg/kg or 10 mg/kg of infliximab by intravenous infusion at weeks 0, 2, and 6 followed by additional infusions every 4 or 8 weeks thereafter. The primary clinical endpoint was the proportion of patients at week 30 who attained an improvement in signs and symptoms as measured by the American College of Rheumatology criteria (ACR20). 42 An ACR 20 response is defined as at least a 20% improvement in both the tender joint count and the swollen joint count (assessments of 28 or more joints) in addition to >20% improvement in 3 of the following 5 core set measures:
• physician global assessment • patient global assessment • patient pain assessment (using a horizontal visual analog scale or Likert-scale assessment)
• patient-assessed disability (based upon any validated, reliable, sensitive instrument, which measures physical function in rheumatoid arthritis patients, e.g., the Health Assessment Questionnaire 43 ) • an acute -phase reactant (erythrocyte sedimentation rate (ESR) or C-reactive protein). 41 Secondary endpoints included documentation of 50% and 70% improvement in ACR criteria, reduction in individual measurements of disease activity, and a general health assessment. Infliximab proved efficacious as judged by all the response criteria used. More patients (P < .001) treated with infliximab, achieved the intention-totreat primary clinical endpoint than in the placebo group. 41 The response was rapid; more than half the ultimate responders attained an ACR20 response by the 2-week evaluation and about 90% at the 6-week evaluation. 
Basiliximab
Basiliximab (Simulect) is a murine-human chimeric monoclonal antibody that specifically binds to and blocks the interleukin-2 receptor alpha-chain (also called CD25 antigen) on the surface of activated T-lymphocytes 44 On 5/12/98, the U.S. Food and Drug Administration (FDA) approved its use as prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids. 45 Approval was granted on the basis of 2 phase III, multicenter, randomized, double-blind, placebocontrolled trials. The EU/CAN study 46 involved 375 patients eligible for intention-to -treat analysis. The U.S. study 47 involved 346 patients. In both trials, patients were randomized to receive either 2 doses of basiliximab or placebo. Basiliximab (20 mg) was administered 2 hours before and then 4 days after transplantation. Both patient groups also received baseline dual immunosuppression with cyclosporine and corticosteroids. 46 The primary clinical endpoint for both trials was the incidence of death, graft loss, or an episode of acute rejection during the first 6 months posttransplantation. 44 Secondary endpoints included the primary endpoint measured during the first 12 months posttransplantation, the incidence of biopsy-confirmed acute rejection during the first 6 and 12 months posttransplantation, and patient survival and graft survival, each measured at 12 months post-transplantation. Patients in both studies receiving basiliximab experienced a significantly lower incidence of biopsy-confirmed rejection episodes at both 6 and 12 months post-transplantation. There were no differences in the rate of delayed graft function, patient survival, or graft survival between basiliximab-treated patients and placebo-treated patients in either study. 46 
Denileukin diftitox
On February 5, 1999, the U.S. Food and Drug Administration approved use of denileukin diftitox (Ontak 49 , DAB389IL-2 50 ) for treating patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the interleukin-2 receptor. 51 Denileukin diftitox is an interleukin-2-receptor-specific ligand fusion protein. 50 It consists of the amino acid sequences for diphtheria toxin fragments A and B followed by the sequences for interleukin-2. 49 Two studies provided the basis for approval. In a phase I/II, multicenter, open-label, dose-ranging study, 35 patients with cutaneous T-cell lymphoma (CTCL) were treated at doses ranging from 3 to 31 mcg/kg/day, daily for 5 days every 3 weeks. 2 Subsequently, a multicenter, randomized, double-blind, phase III study involving 72 patients with recurrent or persistent CTCL were randomized to either 9 or 18 mcg/kg/day of denileukin diftitox administered as an IV infusion daily for 5 days every 3 weeks. 52 Patients received a median of 6 courses. Prior to entry in the studies, patients were screened to ensure expression of the CD25 antigen on at least 20% of the cells in any relevant tumor tissue or circulating cells. All sites of disease were documented at baseline radiographically and by physical examination. Disease assessments were scheduled at 6-week intervals. 50 For both studies, the primary clinical endpoint was based upon attainment of a complete response (no evidence of active disease for 4 or more weeks with no evidence of new disease) or a partial response (reduction of measurable disease greater than or equal to 50% for 4 or more weeks with no evidence of new disease). 2 Secondary clinical endpoints included time to response, duration of response, results of a quality-of-life questionnaire, and the physician's global assessment of CTCL severity. 52 In the phaseI/II study, the overall response rate in patients with CTCL who expressed CD25 was 38%; the complete response rate was 16%, and the partial response rate was 22%. The median time to response was 2 months, and the median duration of response was 10 months. 50 In the phase III study, 30% of patients treated with denileukin diftitox experienced an objective tumor response (>50% reduction in tumor burden sustained for > 6 weeks). Seven patients (10%) achieved a complete response, and 14 patients (20%) achieved a partial response. The median duration of response, measured from the first day of response was 4 months with a median duration for complete response of 9 months and for partial response of 4 months. 49 49 Seragen, Incorporated. Ontak prescribing information. 50 
Etanercept
Etanercept (Enbrel), a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human p75 tumor necrosis factor (TNF) receptor linked to the Fc portion of human IgG1, 53 has been approved by the U.S. Food and Drug Administration for the following indications:
• On November 2, 1998, etanercept was approved for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to one or more diseasemodifying antirheumatic drugs.
• On May 27, 1999, etanercept's biologics license was supplemented to include as an indication for use polyarticular-course juvenile rheumatoid arthritis.
• On June 6, 2000, etanercept was approved for reducing the signs and symptoms and delaying structural damage in patients with moderately to severely active rheumatoid arthritis, including those who have not previously failed treatment with disease-modifying antirheumatic drugs. 54 The safety and clinical efficacy of etanercept for treatment of adult rheumatoid arthritis were assessed in 2 published clinical trials. The study of Moreland et al. 55 examined 234 patients in a phase II, multicenter, randomized, double-blind, placebo-controlled trial. Patients received twice-weekly subcutaneous injections of etanercept, 10 or 25 mg, or placebo for 6 months. The primary clinical endpoints were 20% and 50% improvement in disease activity according to American College of Rheumatology (ACR) responses 56 at 3 and 6 months. An ACR 20 response is defined as at least a 20% improvement in both the tender joint count and the swollen joint count (assessments of 28 or more joints) in addition to >20% improvement in 3 of the following 5 core set measures:
• patient-assessed disability (based upon any validated, reliable, sensitive instrument, which measures physical function in rheumatoid arthritis patients, e.g., the Health Assessment Questionnaire 57 ) • an acute -phase reactant (erythrocyte sedimentation rate or C-reactive protein). 56 At 3 months, 62% of patients receiving 25 mg of etanercept and 23% of the placebo recipients achieved an ACR 20 response (P = .001). At 6 months, 59% of the 25-mg group and 11% of the placebo group achieved an ACR 20 response (P = .001); 40% and 5%, respectively, achieved an ACR 50 response (P = .01). 55 Secondary endpoints were ACR 70 responses at 3 and 6 months and percentage change in the following: tender joint count, swollen joint count, duration of morning stiffness, patients' global assessment, physician's global assessment, patient's assessment of pain, quality of life, erythrocyte sedimentation rate (ESR), and C-reactive protein level. Response was also evaluated according to the Paulus index, defined as a 20% or 50% improvement in at least 4 of the following variables: tender joint scores, swollen joint scores, duration of morning stiffness, ESR, patient's global assessment, and physician's global assessment. 58 Significantly, more etanercept recipients achieved an ACR 70 response, minimal disease status (0 to 5 affected joints), and improved quality of life. Other measures of disease activity, such as C-reactive protein levels, ESR, and duration of morning stiffness were also significantly improved with etanercept treatment. Improvement was observed as early as 2 weeks after initiation of etanercept therapy. 55 A second clinical trial, that of Weinblatt et al., 59 randomized 89 patients, who had additionally received methotrexate for at least 6 months, to etanercept or placebo in addition to methotrexate. The study was conducted in double-blind fashion at multiple centers. The primary clinical endpoint was the proportion of patients meeting the ACR 20 criteria at 24 weeks. Secondary endpoints were the proportion of patients who reached the ACR 20 at 12 weeks, proportions who met the ACR 50 and ACR 70 at 12 and 24 weeks, numbers of swollen and tender joints, 53 Immunex Corporation. Enbrel prescribing information. 54 Center for Biologics Evaluation and Research. www.fda.gov/cber/products/etanimm060600.htm. 55 Proportion of patients at 3, 6, and 12 months who attained a 20%, 50%, or 70% improvement in signs and symptoms as measured by American College of Rheumatology criteria. 56 placebo for 12 months. 53 Clinical endpoints were again based upon the ACR response criteria with the addition of two additional secondary clinical endpoints: (1) results of a health outcome measure, termed the SF-36 questionnaire; and (2) radiographic evaluation of structural joint damage. The SF-36 is a multipurpose, short-form health survey that consists of 36 questions aggregated into 8 scales of 2-10 items each. The SF-36 is a generic measure of health status as opposed to one that targets a specific age, disease, or treatment group. The 8 scales are physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and emotional health. The first 4 scales roll up into the physical health summary measure, and the latter 4 roll up into the mental health summary measure. 60 Patients treated with 25 mg etanercept showed significantly more improvement in the physical health summary score than patients in the 10-mg etanercept group. No significant changes were detected in the mental health summary measure. 53 Structural joint damage was assessed radiographically and expressed as change in total Sharp score. 53 The Sharp score derives from a simplified scheme for assessing abnormalities of rheumatoid arthritis in hand and wrist radiographs. The scheme uses a combination of 17 joints to score erosions and 18 to score joint space narrowing. 61 At 6 and 12 months, patients treated with 25 mg etanercept showed a significant decrease in the erosion score (but not for total Sharp score or joint-space narrowing score) compared to patients treated with methotrexate. 53 The safety and efficacy of etanercept for treating polyarticular course juvenile rheumatoid arthritis was evaluated in a 2-part study of 69 pediatric patients. 62 The first part of the study was an open-label, multicenter study. Those who responded to treatment were then randomized in a double-blind study to receive placebo or etanercept. A response was assessed via a core set of 6 response variables: global assessment of the severity of disease by the physician, global assessment of overall well-being by the patient or parents, number of "active" joints, number of joints with limitation of motion, functional ability, and ESR. 63 The primary clinical endpoint for the double-blind portion of the study was the number of patients with disease flare. Disease flare, as defined for this study, was based on the change in the core set of response variables from the beginning of the double-blind study. Criteria for disease flare were worsening o f 30% or more in 3 of the 6 response variables and a minimum of 2 active joints. They could also have improvement of 30% or more in no more than 1 of the 6 response variables. Global assessments, if used to define flare, had to change by at least 2 units o n a scale from 0 to 10. Secondary endpoints included score in the disability domain of the Childhood Health Assessment Questionnaire, 64, 65 C-reactive protein level, ESR, and white blood cell and platelet counts. In the first part of the study, 74% of patients demonstrated a clinical response and entered part 2. Twenty-four percent of patients remaining on etanercept in part 2 experienced a disease flare, compared to 77% of patients receiving placebo. 62 Etanercept (TNFR:Fc) has also been studied in the context of HIV infection. Both interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) are substances naturally produced by the body's immune system. Elevated TNF-alpha levels can result in increased IL-6 production and possibly increased HIV replication. It has been postulated that exogenous administration of TNF receptors, which bind to and block the action of TNF-alpha, may result in decreased activity of TNF-alpha. 66 Collectively, several laboratory and pilot studies have demonstrated that:
• TNF-alpha production may be excessive or inappropriate in HIV-infected patients 67 and may contribute to declines in CD4+ cell counts. 68 • By decreasing the amount of IL-6 in the body and by decreasing the action of TNF-alpha in the body, TNFR:Fc may have a role in the treatment of HIV disease or in alleviating some of the symptoms related to IL-2 administration. 66 
Immune-based therapies in HIV
Interleukin-2 (aldesleukin)
Aldesleukin (Proleukin 71 ), a human recombinant interleukin-2 (IL-2) product has been approved by the U.S. Food and Drug Administration for two indications:
• On May 5, 1992, it was approved for the treatment of adults 18 years of age or older with metastatic renal cell carcinoma.
• On January 9, 1998, the biologics license was supplemented to include a new indication for use in adults with metastatic melanoma. 72 Over the last 17 years or so, investigators have conducted at least 25 trials of IL-2 in HIV-infected individuals, making it the most extensively studied immune-based therapy in the history of the epidemic. 73 Interleukin-2, in fact, has undergone more thorough evaluation than most antiretroviral therapies, which are now often approved on the basis of surrogate marker data and without clinical endpoint data. Collectively, clinical studies of IL-2 in an HIV setting suggest that: 73 • IL-2, administered intravenously or subcutaneously, produces significant, polyclonal increases in peripheral CD4+ cell counts. 74, 75, 76, 77, 78 • Dramatic rises in CD4+ cell numbers are more likely to be attained in those with less advanced disease; 7980 however, patients with a baseline CD4+ count of less than 200 cells may still benefit when IL-2 is used in conjunction with highly active antiretroviral therapy (HAART).
• CD4+ cells produced as a result of IL-2 therapy are functional. 75 • Despite transient increases in plasma viremia post-infusion, treatment with IL-2 does not cause sustained rises in viral load; 74, 75, 76, 77, 78 viral loads are suppressed from baseline levels in those receiving IL-2 compared to those receiving antiretroviral therapy alone. 81, 82 • Clinical disease progression may occur more slowly among patients receiving IL-2 plus antiviral therapy compared to those receiving antiviral therapy alone. 80 These findings have driven the initiation of large clinical trials. The CPCRA 059 trial 83 was the largest randomized study of IL-2 treatment of early-stage HIV-infected individuals completed to date. The study involved 511 patients with CD4+ counts greater than 300 cells/mm 3 who were already receiving or about to begin antiretroviral therapy. Reports about the effects of IL-2 on viral replication have been inconsistent, with early data suggesting that IL-2 may increase viral loads at least transiently by activating CD4+ cells and a more recent report suggesting that patients responding to aggressive HAART experiencing decreases in viral load with IL-2 treatment. The CPCRA 059 trial addressed this question by using a primary endpoint of proportion of patients with plasma HIV RNA below 50 copies/mL after 1 year on study. 84 After 1 year of follow-up, the proportion of patients with HIV RNA less than 50 copies/mL was 64.4% in the IL-2 arm and 61.7% in the control arm (P = .63). No increase in viral replication with IL-2 treatment was seen during the course of study. As expected, however, the mean CD4+ count increased significantly among patients receiving IL-2 with a mean increase in CD4+ count over the course of the study of 22 cells/mm 3 and 276 cells/mm 3 in the control and IL-2 study arms, respectively (P < .0001). 85 Having elucidated the effects of IL-2 on CD4+ cell counts and HIV RNA levels, all that remains now is to translate these results into clinical outcomes. Presently, 2 large, phase III, clinical-endpoint trials-the ESPRIT 86 and SILCAAT 87 trials-are underway to evaluate IL-2 as an adjunct to antiretroviral therapy for HIV and determine if surrogate markers for HIV disease will lead to long-term clinical benefits for patients. These studies will determine if IL-2 administered with combination antiretroviral therapy will affect progression of AIDS-defining conditions or death, thus providing the first evidence that immune-based therapy can alter the clinical course of HIV infection. 86 www.espritstudy.org. • PBMC from children at a less advanced HIV disease stage appeared to be more likely to have increased HIVspecific cytotoxic lymphocyte (CTL) activity in response to IL-12 than children with more advanced disease 95 • One phase I study showed no marked effects on viral load levels or CD4+ counts in patients receiving singledose treatment. 96 • Repeated subcutaneous injections of IL-12 in patients with cancer resulted in the selective expansion of a subset of peripheral blood CD8+ T-cells. This T-cell subset expressed high levels of CD18 and upregulated IL-12 receptor expression after IL-12 treatment in vivo. 97 • IL-12 therapy of cutaneous T-cell lymphoma induces lesion regression and augments antitumor cytotoxic T-cell responses. 98 • Impaired T-lymphocyte recognition of foreign antigen, including HIV, can be reconstituted in part by supplementation with IL-12 for selected HIV-seropositive individuals. 99 Building upon these initial findings, one phase I study and one phase II study have been undertaken. The goal of the ongoing phase II study 100, 101 is to determine the efficacy and toxicity of EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) chemotherapy in previously untreated AIDS-related lymphoma and to study the effects of IL-12 on immune reconstitution and virologic control in such patients after completion of chemotherapy. Clinical endpoints for the trial include toxicity, response, progression-free survival, and overall survival. Translational endpoints include dynamics of HIV plasma load, CD4+ and CD8+ cell numbers, and functionally defined TH1 and TH2 CD4+ subtypes. Also being monitored are molecular markers of drug resistance (i.e., p53, p16, bcl-2, and MIB-1) and lymphomagenesis (i.e., c-myc, EBV, and HHV-8) in tumor tissue. No details on the number of patients or study design are available.
A completed multicenter, double-blind, randomized, placebo-controlled phase I trial 102103104 evaluated the tolerability of a range of chronic subcutaneous IL-12 d osing regimens in 65 HIV-infected patients with fewer than 50 CD4+ cells/mm 3 , who have no evidence of serious ongoing opportunistic infections and who maintain concomitant antiretroviral therapy. Patients were randomized within one of the three sequential dose cohorts and received either IL-12 or placebo. The primary endpoint of the study was the occurrence, 8 weeks or less after the initiation of study drug treatment, of either: (a) Grade 3 toxicity judged to be definitely related or possibility related to study medication, or (b) a Grade 4 toxicity or death judged to be definitely related, possibly related, or whose relationship to study medication is unable to be judged by the local investigator. Secondary endpoints were the change from baseline to posttreatment in serum interferon-gamma level; serum neopterin level; lymphoproliferative responses of PBMCs to MAC antigen; type 1 Th responses (i.e., inducible interferon-gamma) to mitogens and alloantigens; absolute count of CD4+, CD8+, CD3-/CD16+/CD56+ cells; lymphoproliferative responses to tetanus toxoid, Candida, streptokinase, and HIV antigens with PHA as a control; delayed-type hypersensitivity skin tests; and plasma HIV-1 RNA copy number. This study has closed enrollment, and the results are being analyzed.
matching the canarypox/HIV-1 immunogen and gp-120. The assay was considered to be positive when the percent lysis of infected targets was greater than 10% above that of control vaccinia. 142 This phase II trial found that the vCP205 prime-boost combination was safe and capable of inducing neutralizing antibodies in half of volunteers receiving vCP205 alone and more than 90% of those receiving the primeboost combination. Furthermore, measurable cellular immune responses were elicited in approximately one-third of those immunized. 143 Additional phase I/II trials are underway to compare additional canarypox vector vaccines to assess which may be best for evaluation in larger trials. 144 A recent report 145 notes the lack of a validated correlate of protective immunity against HIV infection, and, consequently, no validated criterion is available for moving experimental HIV vaccines forward into phase II trials. Induction of neutralizing antibodies and induction of specific cytotoxic T-lymphocyte precursors are the consensus goals of current vaccine development initiatives sponsored by the National Institutes of Health, but these goals have not been consistently shown to correlate with protection. Low or undetectable plasma viremia is the current "gold standard" for predicting AIDS-free survival, but it is not a useful parameter for assessing immune status in uninfected vaccine recipients. Described in the article is an in vitro assay developed as a correlate of vaccine-induced protection from HIV. The assay uses cultures of PBMC, which are challenged with two strains of HIV to gauge resistance. Among 34 HIV vaccine recipients of canarypox vaccine, PBMC from postvaccination samples were significantly resistant to both strains, and cytotoxic T-lymphocyte precursor-positive samples were significantly more resistant than were precursor-negative samples. The assay was validated in populations with relative resistance to HIV-1 as well as in HIV vaccine recipients. This study provided the first evidence of the induction by vaccination of a validated correlate of protection. 145 Another recently reported development that may have relevance to the search for surrogate markers of protective immunity against HIV is a report on cytokine profiles of individuals receiving the vCP205 prime-boost vaccine regimen. 146 Cytokines were measured by enzyme linked immunosorbent assay in culture supernatants of PBMC collected from the vaccine recipients at multiple time points. Peak responses varied by individual and by specific cytokine. It was noted, however, that all prime-boost recipients experienced peak responses at a time point following the boost administration. The PBMC of all prime-boost vaccinated individuals produced detectable interferon-gamma and interleukin-10 in response to stimulation with HIV-1 envelope glycoprotein antigens; 83% also had detectable levels of IL-2 and IL-6, 71% had detectable levels of IL-4, and 86% had detectable levels of IL-5.
